What’s striking in these PFE and AMGN slide sets is the degree of overlap—all five FoBs in PFE’s pipeline (excluding what will be acquired from HSP) are in AMGN’s pipeline: Humira, Avastin, Herceptin, Rituxan, and Remicade.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”